AspyreRx, a Digital Behavioral Therapeutic for Type 2 Diabetes, Now Available

AspyreRx™ is now available for use as a prescription digital behavioral therapeutic device for adults with type 2 diabetes.

The device is intended to provide cognitive behavioral therapy (CBT), as an adjunct to standard of care, to patients aged 18 years and older with type 2 diabetes under the care of a health care provider. Prescribed in 90-day increments, the digital therapeutic delivers CBT through a mobile application in a weekly, step-by-step process to help patients improve glycemic control.

The Food and Drug Administration (FDA) approved AspyreRx in July 2023 based on data from a phase 3 trial (ClinicalTrials.gov Identifier: NCT04886388) that included 669 patients with type 2 diabetes. Patients were randomly assigned to receive AspyreRx or a control app, in addition to standard of care. 

Study findings showed use of AspyreRX led to statistically significant reductions in HbA1c at 90 and 180 days vs control. Patients in the AspyreRx group also achieved statistically significant improvements in blood pressure, weight, fasting glucose, mood, and quality of life. They also used less medication and had fewer adverse events compared with those in the control group. 

“With the launch of AspyreRx, providers now have a clinically proven treatment delivered in an easily accessible, engaging and affordable way,” said Frank Karbe, Chief Executive Officer of Better Therapeutics. “Behavior modification can be powerful medicine that is valuable at any stage of the disease and since it is already included in current treatment guidelines, we envision AspyreRx becoming part of the standard of care for adults with T2D.”

AspyreRx is available in the Apple App and Google Play stores. Additional information for prescribers can be found here.

This article originally appeared on MPR